NO982878D0 - Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer - Google Patents

Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer

Info

Publication number
NO982878D0
NO982878D0 NO982878A NO982878A NO982878D0 NO 982878 D0 NO982878 D0 NO 982878D0 NO 982878 A NO982878 A NO 982878A NO 982878 A NO982878 A NO 982878A NO 982878 D0 NO982878 D0 NO 982878D0
Authority
NO
Norway
Prior art keywords
inhibition
treatment
proliferative diseases
protein function
amides useful
Prior art date
Application number
NO982878A
Other languages
English (en)
Other versions
NO318232B1 (no
NO982878L (no
Inventor
Ronald J Doll
Joseph M Kelly
George F Njoroge
Alan K Mallams
Stacy W Remiszewski
Arthur G Taveras
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO982878D0 publication Critical patent/NO982878D0/no
Publication of NO982878L publication Critical patent/NO982878L/no
Publication of NO318232B1 publication Critical patent/NO318232B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
NO19982878A 1995-12-22 1998-06-19 Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og anvendelse av disse forbindelsene for fremstilling av et medikament for behandling av proliferative sykdommer NO318232B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57795195A 1995-12-22 1995-12-22
US61576096A 1996-03-13 1996-03-13
PCT/US1996/019603 WO1997023478A1 (en) 1995-12-22 1996-12-19 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
NO982878D0 true NO982878D0 (no) 1998-06-19
NO982878L NO982878L (no) 1998-08-24
NO318232B1 NO318232B1 (no) 2005-02-21

Family

ID=27077386

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982878A NO318232B1 (no) 1995-12-22 1998-06-19 Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og anvendelse av disse forbindelsene for fremstilling av et medikament for behandling av proliferative sykdommer

Country Status (24)

Country Link
EP (2) EP1380581A1 (no)
JP (1) JP3193725B2 (no)
KR (1) KR100295224B1 (no)
CN (1) CN1326847C (no)
AR (1) AR005152A1 (no)
AT (1) ATE309238T1 (no)
AU (1) AU730194B2 (no)
BR (1) BR9612203A (no)
CA (2) CA2358394C (no)
CZ (1) CZ292791B6 (no)
DE (1) DE69635424T2 (no)
DK (1) DK1019392T3 (no)
ES (1) ES2248826T3 (no)
HK (1) HK1025571A1 (no)
HU (1) HU228352B1 (no)
IL (1) IL125062A (no)
MX (1) MX9804956A (no)
MY (1) MY119007A (no)
NO (1) NO318232B1 (no)
NZ (1) NZ326035A (no)
PL (1) PL185597B1 (no)
SK (1) SK86198A3 (no)
TW (1) TW350844B (no)
WO (1) WO1997023478A1 (no)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO1998004549A1 (en) * 1996-07-26 1998-02-05 Schering Corporation Method for preparing substituted 1-piperidinecarboxamide derivatives
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
ES2235252T3 (es) * 1996-09-13 2005-07-01 Schering Corporation Inhibidores triciclicos de la farnesil proteina transferasa.
KR20000036111A (ko) * 1996-09-13 2000-06-26 둘락 노먼 씨. 파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
SK33599A3 (en) * 1996-09-13 2000-03-13 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
CZ84599A3 (cs) * 1996-09-13 1999-07-14 Schering Corporation Sloučeniny vhodné pro inhibici farnesyl protein transferasy
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
ID22067A (id) * 1996-09-13 1999-08-26 Schering Corp Senyawa-senyawa yang berguna untuk inhibisi transferase protein farnesil
EP0927181A1 (en) * 1996-09-13 1999-07-07 Schering Corporation Tricyclic compounds useful as fpt inhibitors
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
BR9807418A (pt) * 1997-02-18 2002-01-22 Canji Inc Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US5998620A (en) * 1997-03-25 1999-12-07 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
JP2002504150A (ja) * 1997-06-17 2002-02-05 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの新規フェニル置換三環式インヒビター
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
CA2293713C (en) * 1997-06-17 2006-12-05 Schering Corporation Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
EP0989979A1 (en) * 1997-06-17 2000-04-05 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
BR9814419A (pt) * 1997-12-22 2000-10-10 Schering Corp "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
MY126580A (en) * 1997-12-22 2006-10-31 Merck Sharp & Dohme Molecular dispersion composition with enchanced bioavailabity
AU4828299A (en) * 1998-07-02 2000-01-24 Schering Corporation Process for producing (8- chloro-3,10- dibromo-6,11- dihydro- 5h-benzo (5,6)cyclohepta (1,2-b)pyridin-11-yl)- 1-piperidine
US6706883B1 (en) * 1998-07-02 2004-03-16 Schering Corporation Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-B]pyridin-11-YL)-1-piperdine
US6535820B1 (en) * 1998-08-28 2003-03-18 Schering Corporation Crystalline farnesyl protein transferase compositions and methods for use
US6372909B1 (en) 1998-11-20 2002-04-16 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
DE69905604T2 (de) * 1998-11-20 2003-12-04 Schering Corp Enantioselective alkylierung von trizyklischen verbindungen
AU3790200A (en) 1998-11-20 2000-06-13 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
HUP0302104A2 (hu) * 2000-11-29 2003-09-29 Schering Corp. Új farnezil-protein-transzferáz inhibitorok
TW200412956A (en) * 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
CN101289425B (zh) * 2002-10-03 2011-04-13 先灵公司 三环化合物的对映选择性烷基化
ATE417041T1 (de) 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009145852A1 (en) * 2008-04-17 2009-12-03 Concert Pharmaceuticals, Inc. Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
WO2010057028A2 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR20160072352A (ko) 2014-12-12 2016-06-23 동보씨엠텍산업(주) 저위투입구 믹서로더
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
KR20190140454A (ko) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
DK0723538T3 (da) * 1993-10-15 2002-03-18 Schering Corp Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CZ292791B6 (cs) 2003-12-17
MX9804956A (es) 1998-09-30
CZ193898A3 (cs) 1998-10-14
JPH11501671A (ja) 1999-02-09
HUP9903705A3 (en) 2002-04-29
MY119007A (en) 2005-03-31
ATE309238T1 (de) 2005-11-15
EP1019392B1 (en) 2005-11-09
IL125062A0 (en) 1999-01-26
KR19990076655A (ko) 1999-10-15
WO1997023478A1 (en) 1997-07-03
NZ326035A (en) 2000-01-28
AU1331197A (en) 1997-07-17
HUP9903705A2 (hu) 2000-05-28
DE69635424T2 (de) 2006-08-03
PL185597B1 (pl) 2003-06-30
KR100295224B1 (ko) 2001-09-17
DK1019392T3 (da) 2006-03-20
NO318232B1 (no) 2005-02-21
HK1025571A1 (en) 2000-11-17
AU730194B2 (en) 2001-03-01
CN1209127A (zh) 1999-02-24
DE69635424D1 (de) 2005-12-15
PL327312A1 (en) 1998-12-07
BR9612203A (pt) 1999-07-13
JP3193725B2 (ja) 2001-07-30
AR005152A1 (es) 1999-04-14
NO982878L (no) 1998-08-24
CA2240846A1 (en) 1997-07-03
CN1326847C (zh) 2007-07-18
TW350844B (en) 1999-01-21
EP1019392A1 (en) 2000-07-19
CA2240846C (en) 2002-07-16
ES2248826T3 (es) 2006-03-16
IL125062A (en) 2003-11-23
HU228352B1 (en) 2013-03-28
SK86198A3 (en) 1999-02-11
EP1380581A1 (en) 2004-01-14
CA2358394A1 (en) 1997-07-03
CA2358394C (en) 2006-05-02

Similar Documents

Publication Publication Date Title
NO982878D0 (no) Trisykliske amider som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
NO974610D0 (no) Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
DE69626104T2 (de) Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und zur behandlung von proliferativen erkrankungen
NO962179D0 (no) Fremgangsmåte for fremstilling av metallocen og anvendelse derav
NO961006L (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
FI964874A (fi) Vihannesten käsittely
IL117603A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5307796A (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5307696A (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NO976063D0 (no) Fremgangsmåte for behandling av diabetes
NO973836L (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
AU6594796A (en) Photoactivatable compounds for the prevention of intimal hyperplasia and other diseases
DE69612465T2 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
NO991382L (no) Mellomprodukter og fremgangsmÕte for fremstilling av olanzapin
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
NO983512D0 (no) Midler for behandling og forhindring av AIDS
IL117797A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NO944931D0 (no) Anvendelse av 2-fenyl-3-arroylbenzotiofener for inhibering av tidlig seksuell modenhet
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte
DE69412178D1 (de) Apparat zur Behandlung von Lagen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MK1K Patent expired